HUP0000569A2 - Ekvilenin alkalmazása szabadgyökök által indukált betegségek elleni gyógyszerkészítmények előállítására - Google Patents
Ekvilenin alkalmazása szabadgyökök által indukált betegségek elleni gyógyszerkészítmények előállításáraInfo
- Publication number
- HUP0000569A2 HUP0000569A2 HU0000569A HUP0000569A HUP0000569A2 HU P0000569 A2 HUP0000569 A2 HU P0000569A2 HU 0000569 A HU0000569 A HU 0000569A HU P0000569 A HUP0000569 A HU P0000569A HU P0000569 A2 HUP0000569 A2 HU P0000569A2
- Authority
- HU
- Hungary
- Prior art keywords
- equilenin
- disease
- disease states
- treatment
- pharmaceutical compositions
- Prior art date
Links
- PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- PDRGHUMCVRDZLQ-WMZOPIPTSA-N equilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-WMZOPIPTSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003254 radicals Chemical class 0.000 title 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 201000004193 respiratory failure Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract 1
- 206010014561 Emphysema Diseases 0.000 abstract 1
- 206010019755 Hepatitis chronic active Diseases 0.000 abstract 1
- 206010019799 Hepatitis viral Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000018109 developmental process Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 201000001862 viral hepatitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A találmány ekvilenin vagy ekvilenin-3-szulfát-észtergyógyszerészetileg elfogadható sójának az alkalmazására vonatkozikszabadgyökök által indukált betegségi állapotok enyhítésére vagykezelésére alkalmas gyógyszer előállításában, közelebbről rákfélék,központi idegrendszeri rendellenességek, Alzheimer-kór, csontbetegség,öregedés, gyulladásos rendellenességek, perifériális vaszkulárisbetegség, reumatoid arthritis, autoimmun betegségek, légzőszervielégtelenség, emphysema, reperfúzióssérülés-megelőzés, virálishepatitisz, krónikus aktív hepatitisz, tuberkulózis, pszoriázis,szisztémiás lupus eriythematosus, felnőttkori légzőszervielégtelenségi szindróma, központi idegrendszeri trauma és stroke vagyreperfúziós eljárások alatti sérüléseknek a kialakulásában szerepetjátszó endogén szabadgyökök gátlására alkalmas gyógyszerelőállításában. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76257996A | 1996-12-10 | 1996-12-10 | |
| PCT/US1997/022154 WO1998025626A1 (en) | 1996-12-10 | 1997-12-05 | Use of equilenin as an antioxidant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0000569A2 true HUP0000569A2 (hu) | 2000-10-28 |
| HUP0000569A3 HUP0000569A3 (en) | 2000-11-28 |
Family
ID=25065472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0000569A HUP0000569A3 (en) | 1996-12-10 | 1997-12-05 | Use of equilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0944391A1 (hu) |
| JP (1) | JP2001506628A (hu) |
| KR (1) | KR20000069412A (hu) |
| CN (1) | CN1239892A (hu) |
| AR (1) | AR010344A1 (hu) |
| AU (1) | AU743586B2 (hu) |
| BR (1) | BR9714384A (hu) |
| CA (1) | CA2272087A1 (hu) |
| HU (1) | HUP0000569A3 (hu) |
| IL (1) | IL130071A0 (hu) |
| NZ (1) | NZ336343A (hu) |
| TW (1) | TW466115B (hu) |
| WO (1) | WO1998025626A1 (hu) |
| ZA (1) | ZA9711052B (hu) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6271221B1 (en) * | 1996-12-10 | 2001-08-07 | American Home Products Corporation | Use of equilenin as an antioxidant |
| DE19915576A1 (de) | 1999-03-30 | 2000-10-05 | Jenapharm Gmbh | Equileninderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| ATE517617T1 (de) * | 2001-12-10 | 2011-08-15 | Yansheng Dr Du | Behandlung von parkinson erkrankung mit kape |
| CN108958639B (zh) | 2017-05-19 | 2021-07-06 | 华邦电子股份有限公司 | 快闪存储器存储装置 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4154820A (en) * | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
| EP0240717A3 (en) * | 1986-03-04 | 1990-05-16 | Board of Regents of the University of Nebraska | Prevention of mammary carcinoma |
| US4937238A (en) * | 1986-03-04 | 1990-06-26 | The Board Of Regents Of The University Of Nebraska | Prevention of mammary carcinoma |
| US5545635A (en) * | 1995-05-23 | 1996-08-13 | Eli Lilly And Company | Inhibiting bone loss with equilenin |
-
1997
- 1997-11-27 TW TW086117838A patent/TW466115B/zh not_active IP Right Cessation
- 1997-12-05 CN CN97180448A patent/CN1239892A/zh active Pending
- 1997-12-05 JP JP52680498A patent/JP2001506628A/ja not_active Ceased
- 1997-12-05 KR KR1019997005181A patent/KR20000069412A/ko not_active Application Discontinuation
- 1997-12-05 AU AU53707/98A patent/AU743586B2/en not_active Ceased
- 1997-12-05 EP EP97950808A patent/EP0944391A1/en not_active Withdrawn
- 1997-12-05 NZ NZ336343A patent/NZ336343A/xx unknown
- 1997-12-05 HU HU0000569A patent/HUP0000569A3/hu unknown
- 1997-12-05 WO PCT/US1997/022154 patent/WO1998025626A1/en not_active Application Discontinuation
- 1997-12-05 BR BR9714384-7A patent/BR9714384A/pt not_active IP Right Cessation
- 1997-12-05 CA CA002272087A patent/CA2272087A1/en not_active Abandoned
- 1997-12-05 IL IL13007197A patent/IL130071A0/xx unknown
- 1997-12-09 ZA ZA9711052A patent/ZA9711052B/xx unknown
- 1997-12-09 AR ARP970105778A patent/AR010344A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9714384A (pt) | 2000-05-16 |
| KR20000069412A (ko) | 2000-11-25 |
| ZA9711052B (en) | 1999-06-09 |
| CN1239892A (zh) | 1999-12-29 |
| AR010344A1 (es) | 2000-06-07 |
| AU743586B2 (en) | 2002-01-31 |
| TW466115B (en) | 2001-12-01 |
| CA2272087A1 (en) | 1998-06-18 |
| WO1998025626A1 (en) | 1998-06-18 |
| AU5370798A (en) | 1998-07-03 |
| EP0944391A1 (en) | 1999-09-29 |
| IL130071A0 (en) | 2000-02-29 |
| JP2001506628A (ja) | 2001-05-22 |
| HUP0000569A3 (en) | 2000-11-28 |
| NZ336343A (en) | 2000-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20013859L (no) | Cyklooksygenase-2 inhibitoriske medikamenter med rask inntreden av terapeutisk virkning | |
| SG52443A1 (en) | Methods and compositions for the treatment of disease with interferon while reducing sid effects | |
| DE69327582D1 (de) | Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| NO934768D0 (no) | Sammensetning av L-DOPA-estere | |
| SE9701956D0 (sv) | New composition of matter | |
| DK0713701T3 (da) | 2-Brommelatonin til behandling af søvnforstyrrelser | |
| GB9606736D0 (en) | Therapeutic method | |
| HU9600832D0 (en) | Inhibitors of beta-amyloid protein production | |
| JP2017535612A5 (hu) | ||
| DK0668763T3 (da) | Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| WO2005014041A3 (en) | Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases | |
| DE3480053D1 (en) | A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor | |
| ZA912652B (en) | Use of n-alkylated 1,4-dihydropyridinedicarboxylic acid esters as medicaments,new compounds and processes for their preparation | |
| HUP0000569A2 (hu) | Ekvilenin alkalmazása szabadgyökök által indukált betegségek elleni gyógyszerkészítmények előállítására | |
| WO2003077832A3 (en) | Dexanabinol and dexanabinol analogs regulate inflammation related genes | |
| BG103687A (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system | |
| HUP0000570A2 (hu) | 17 Alfa-dihidroekvilenin alkalmazása szabadgyökök által indukált betegségek elleni gyógyszerkészítmények előállítására | |
| HUP0000476A2 (hu) | 17 Béta-dihidroekvilenin alkalmazása szabadgyökök által indukált betegségek elleni gyógyszerkészítmények előállítására | |
| DE69813070D1 (de) | Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex | |
| CA2374997A1 (en) | Il6ril6 chimera for the treatment of neurodegenerative diseases | |
| KR970009812A (ko) | 활성화 면역글로불린 | |
| GR3022205T3 (en) | New derivatives of physostigmine, their use and pharmaceutical formulations containing them | |
| WO2001074339A3 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |